Companies: 10,795·Total market cap: $144.5T
Myovant Sciences Ltd.

Myovant Sciences Ltd.

MYOVNYSEHealthcare
$26.98
$-0.01(-0.04%)
Market Cap$2.6B
P/E Ratio—
52W High$27.06
52W Low$7.67
RevenueFinancialsEarnings

Myovant Sciences Ltd. (MYOV) Revenue

Annual & quarterly revenue history · segment & region breakdown

MYOV · revenue · updated Jun 9, 2026

Core revenue metrics

Myovant Sciences Ltd. trailing twelve-month (TTM) revenue is $0.38B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.38B
4-quarter sum · USD
YoY growth
+0.00%
vs FY —
Price / sales
6.92×
mktCap ÷ TTM rev
Revenue per day
$1M
Est. TTM ÷ 365
Revenue / employee
$655K
579 employees
FY
—
FY
—
5Y CAGR
—
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Myovant Sciences Ltd. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

– · Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
MYOV revenue by year · MYOV revenue history · MYOV annual revenue data

Compare revenue vs peers

Biotechnology

Compare MYOV revenue against listed peers. Click any row to open that company's revenue tab.

MorphoSys AG
MorphoSys AG
MOR · $11.4B
→
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc.
SWTX · $3.5B
→
Morphic Holding, Inc.
Morphic Holding, Inc.
MORF · $2.9B
→
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc.
KDNY · $2.7B
→
Provention Bio, Inc.
Provention Bio, Inc.
PRVB · $2.4B
→
Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc.
LBPH · $2.3B
→

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Myovant Sciences Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Myovant Sciences Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Myovant Sciences Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.
Price historyFinancial statementsForecast

Frequently asked questions

MYOV revenue · 4 questions

MYOV's trailing twelve-month (TTM) revenue is $0.38B. That is an increase of 0.00% year-over-year from — in FY.

MYOV revenueMYOV annual revenuewhat is MYOV revenueMYOV TTM revenue

▸ Source: FMP · Myovant Sciences Ltd. SEC filings · GAAP · Myovant Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026